📰 Selecta Imm News
Selecta Imm News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Selecta Imm. Real-time updates on events, politics, business and more.
October 31, 2023
31.10.2023 - WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) - Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, ... Seite 1
October 31, 2023
By Sabela Ojea Selecta Biosciences has agreed to transfer its manufacturing and development rights and remaining clinical operations for its Sel-212 medicine...
March 28, 2023
FDA Approval of New Gout Drug Likely, Analyst Says
March 22, 2023
Swedish Orphan Biovitrum AB or Sobi (SWTUY.PK), a specialised biopharmaceutical company, and Selecta Biosciences, Inc. (SELB) announced Tuesday positive topline results from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout.
December 22, 2021
4 penny stocks with bullish price targets & buy ratings from analysts.
December 1, 2021
/PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced the completion of...
December 1, 2021
/PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced the completion of...
December 1, 2021
STOCKHOLM, Dec. 1, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced the completion of enrolment for DISSOLVE
April 21, 2021
An Analysis Of The Gene Therapy Viral Vector Landscape By Kyle M. O’Neil and Brendan J. Wang, Back Bay Life Science Advisors Over the last five years, multiple gene therapies have been approved by regulatory agencies and a bolus of late-stage pipeline assets are approaching the market. As the first few gene therapies realize their potential as transformative treatments for the genetic rare diseases, the space is seen as a crucial part of growth for the biopharmaceutical industry. However, as ...
February 8, 2021
02.08.21 -- Business Of Biotech Introduces The Cell And Gene Series - New Episodes Out Now! Business of Biotech and Life Science Connect. As a member of the Life Science Connect community you have access to content beyond our weekly newsletters, including our podcast series. Don’t forget to subscribe so that you never miss an episode! On the latest episode of Business of Biotech, Lineage Cell Therapeutics CEO, Brian Culley, explains how he kept the companys programs for OpRe...